KAREN J KLAMERUS
Pharmacy in San Diego, CA

License number

Pennsylvania RP036338R

Personal information

See more information about KAREN J KLAMERUS at radaris.com

Name

Address

Phone

Karen Klamerus

Del Mar, CA

(858) 356-9573

Karen J Klamerus, age 67

4877 Bayliss Ct, San Diego, CA 92130

(858) 703-4953
(858) 356-9573

Karen J Klamerus, age 67

2 Brady Pl, Menlo Park, CA 94025

Professional information

Senior Director At Pfizer, Inc

Position:

Senior Director at Pfizer, Inc

Location:

Greater San Diego Area

Industry:

Pharmaceuticals

Work:

Pfizer, Inc - Greater San Diego Area since 2004 - Senior Director Pfizer, Inc - Greater San Diego Area 2002 - 2004 - Director, Clinical Development Vical, Inc - Greater San Diego Area 2002 - 2002 - Director, Clinical Research & Data Management Hoffmann-La Roche 1997 - 2001 - Director, Medical Research Wyeth Research - Radnor, Pennsylvania 1995 - 1997 - Associate Director

Education:

University of Illinois at Chicago
BS, Pharmacy University of Kentucky
Pharm.D., Pharmacy University of Nebraska at Omaha
Residency, Pharmacy

Therapeutic Combinations Comprising Poly (Adp-Ribose) Polymerases Inhibitor

US Patent:

2006007, Apr 6, 2006

Filed:

Sep 20, 2005

Appl. No.:

11/231470

Inventors:

Heidi Marie Steinfeldt - San Diego CA, US
Theodore James Boritzki - San Diego CA, US
Alan Hilary Calvert - Blaydon-on-Tyne, GB
Nicola Jane Curtin - Rowlands Gill, GB
Mohamed Raza Dewji - Harrow, GB
Zdenek Hostomsky - La Jolla CA, US
Christopher Jones - Gosforth, GB
Rhonda Kaufman - Bridgewater NJ, US
Karen Klamerus - San Diego CA, US
David Richard Newell - Humshaugh, GB
Elizabeth Ruth Plummer - Heddon-on-the-Wall, GB
Steven Reich - Del Mar CA, US
Ian Stratford - Manchester, GB
Huw David Thomas - Houghton-le-Spring, GB
Kay Janine Williams - Middleton, GB

International Classification:

A61K 31/55

US Classification:

514212060

Abstract:

This invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy. This invention provides pharmaceutical combinations of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, kits containing such combinations and methods of using such combinations to treat subjects suffering from diseases such as cancer.